J. Balko

发表

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

J. Balko, M. Sanders, L. Gianni, 2016, Nature Reviews Clinical Oncology.

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

R. Yelensky, J. Ross, M. Cronin, 2014, Cancer discovery.

Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum

J. Sosman, Douglas B. Johnson, J. Balko, 2016, Pigment cell & melanoma research.

Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution.

J. Balko, Andrew Williams, D. Brantley-Sieders, 2014, The Journal of clinical investigation.

Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

Yu Wang, Zlatko Trajanoski, Clemens Mayer, 2017, Genome Medicine.

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Yu Shyr, Xingyi Guo, James X. Sun, 2016, Cancer Immunology Research.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe

Carsten Denkert, Fred Hirsch, Benjamin Solomon, 2017, Advances in anatomic pathology.

Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.

Phillip Owens, Rebecca S Cook, Carlos L Arteaga, 2013, Cancer research.

Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer

Carlos L. Arteaga, Gordon B. Mills, Robert E. Brown, 2013, Clinical Cancer Research.

Intratumoral Delivery of Paclitaxel in Solid Tumor from Biodegradable Hyaluronan Nanoparticle Formulations

Justin M. Balko, J. Balko, E. P. Black, 2009, AAPS PharmSciTech.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

Marieke E. Ijsselsteijn, Z. Trajanoski, Douglas B. Johnson, 2018, bioRxiv.

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

S. Mallal, J. Sosman, P. Gonzalez-Ericsson, 2019, Nature Medicine.

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

J. Berlin, W. Pao, J. Sosman, 2014, The oncologist.

Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy

Douglas B. Johnson, J. Balko, J. Moslehi, 2020, British journal of clinical pharmacology.

Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.

G. Mills, J. Balko, A. González-Angulo, 2011, Cancer research.

Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors

Joseph T. Roland, P. Gonzalez-Ericsson, J. Balko, 2020, Science Translational Medicine.

Immune-checkpoint inhibitors: long-term implications of toxicity

Douglas B. Johnson, J. Balko, J. Moslehi, 2022, Nature Reviews Clinical Oncology.

A tumor-intrinsic PD-L1-NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.

Douglas B. Johnson, J. Balko, A. Nixon, 2020, The Journal of clinical investigation.

First-Line Treatment of Metastatic Colorectal Cancer: Focus on Cetuximab in Combination with Chemotherapy

J. Balko, E. P. Black, Allison L. Balko, 2010 .

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer

E. Winer, M. Berger, L. Cantley, 2016, Clinical Cancer Research.

Emerging biomarkers for cancer immunotherapy in melanoma.

Douglas B. Johnson, J. Balko, M. Axelrod, 2017, Seminars in cancer biology.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

L. Garraway, X. Mu, R. Yelensky, 2017, Science Translational Medicine.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma*

Douglas B. Johnson, J. Balko, D. Liebler, 2017, Molecular & Cellular Proteomics.

Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature

J. Balko, E. P. Black, E. Black, 2009, Cancer biology & therapy.

Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer

J. Balko, M. V. Estrada, M. Sanders, 2022, Breast cancer research : BCR.

Abstract 3328: MYC and MCL1 cooperatively promote chemotherapy-resistant cancer stem cells through regulation of mitochondrial biogenesis and oxidative phosphorylation

J. Giltnane, J. Balko, Kyung-Min Lee, 2016 .

Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.

R. Sullivan, Douglas B. Johnson, J. Balko, 2020, The Lancet. Oncology.

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.

Marc P. Bonaca, D. Roden, A. Pariente, 2018, The Lancet. Oncology.

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

A. Guerrero-Zotano, J. Balko, M. Sanders, 2018, Clinical Cancer Research.

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

D. Cescon, B. Vincent, S. Adams, 2019, npj Breast Cancer.

Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies.

A. Mahadevan-Jansen, J. Balko, O. Ayala, 2019, ACS nano.

Kinome wide functional screen identifies role of Polo-like kinase 1 (PLK1) in hormone-independent, ER-positive breast cancer

J. Giltnane, J. Balko, M. Sanders, 2014 .

Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy

P. Massion, Douglas B. Johnson, J. Balko, 2017, JCO precision oncology.

Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: A pharmacovigilance study

Marc P. Bonaca, D. Roden, A. Pariente, 2018 .

Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer

P. Gonzalez-Ericsson, Douglas B. Johnson, J. Balko, 2020, medRxiv.

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2

P. Gonzalez-Ericsson, Douglas B. Johnson, J. Balko, 2018, Oncoimmunology.

Primed for toxicity: CD4+ T cells and immune checkpoint inhibitors.

Douglas B. Johnson, J. Balko, 2022, Med.

ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation

J. Balko, M. M. Joly, R. Cook, 2017, Breast Cancer Research.

Peripheral Blood Monocyte Abundance Predicts Outcomes in Breast Cancer Patients

B. Seliger, P. Gonzalez-Ericsson, A. Guerrero-Zotano, 2021, Cancer Research Communications.

Maybe we don't know JAK?

J. Balko, L. Schwarz, 2016, Molecular & cellular oncology.

PIK 3 CA C 2 domain deletions hyperactivate phosphoinositide 3-kinase ( PI 3 K ) , generate oncogene dependence and are exquisitely sensitive to PI 3 Kα inhibitors

L. Cantley, J. Meiler, V. Miller, 2017 .

Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.

Douglas B. Johnson, J. Balko, M. Wilson, 2019, The oncologist.

Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer

E. Petricoin, L. Pusztai, H. Gómez, 2021, Clinical Cancer Research.

Tumor-Speci ﬁ c Major Histocompatibility-II Expression Predicts Bene ﬁ t to Anti – PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer

L. Pusztai, H. Gómez, P. Gonzalez-Ericsson, 2021 .

SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC).

E. Winer, J. Yap, J. Balko, 2012 .

Cytotoxic T cells speci�c for alpha-myosin drive immunotherapy related myocarditis

S. Mallal, M. Carroll, Douglas B. Johnson, 2022 .

Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?

Douglas B. Johnson, J. Balko, 2018, Clinical Cancer Research.

A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?

J. Sosman, J. Balko, 2018, Cancer discovery.

T cells specific for α-myosin drive immunotherapy-related myocarditis

S. Mallal, M. Carroll, Douglas B. Johnson, 2022, Nature.

RNA-Sequencing Reveals a Distinct Transcriptomic Signature for Giant Cell Myocarditis and Identifies Novel Druggable Targets.

J. Balko, Yaomin Xu, J. Moslehi, 2021, Circulation research.

Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer

James X. Sun, P. Stephens, R. Yelensky, 2014, Clinical Cancer Research.

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

C. Zahnow, P. Gonzalez-Ericsson, J. Balko, 2018, Nature Communications.

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Adrian V. Lee, Gregory L. Wheeler, E. Mardis, 2022, Nature Cancer.

Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

J. Seidman, J. Taube, D. Roden, 2016, The New England journal of medicine.

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.

S. Fesik, H. Gómez, K. Hutchinson, 2017, Cell metabolism.

Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma

J. Balko, John T. Wilson, Lihong Wang-Bishop, 2020, Journal for ImmunoTherapy of Cancer.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

R. Sullivan, W. Rathmell, J. Sosman, 2018, JAMA oncology.

Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.

J. Balko, H. Koblish, P. Scherle, 2018, Cancer research.

Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial

J. Balko, S. Lofgren, D. Boulware, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial

J. Balko, S. Lofgren, D. Boulware, 2020, medRxiv.

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

D. Cescon, B. Vincent, S. Adams, 2019, npj Breast Cancer.

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

A. D. Van den Abbeele, E. Winer, L. Cantley, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

C. Perou, J. Balko, Hailing Cheng, 2013, Proceedings of the National Academy of Sciences.

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

J. Balko, C. Arteaga, T. Miller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.

G. Mills, M. Dowsett, J. Balko, 2011, Cancer discovery.

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

S. Loi, J. Trapani, P. Savas, 2017, Nature Communications.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

S. Mallal, R. Yelensky, S. Loi, 2015, Clinical Cancer Research.

MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion.

J. Balko, Jingchun Gao, S. Altiok, 2009, International journal of oncology.

ERa-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

G. Mills, M. Dowsett, J. Balko, 2011 .

Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

G. Mills, M. Dowsett, J. Balko, 2011 .

Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.

C. Perou, J. Balko, Hailing Cheng, 2013, Cancer research.

Therapeutics , Targets , and Chemical Biology Conditional Loss of ErbB 3 Delays Mammary Gland Hyperplasia Induced by Mutant PIK 3 CA without Affecting Mammary Tumor Latency , Gene Expression , or Signaling

C. Perou, J. Balko, Hailing Cheng, 2013 .

Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers

J. Balko, W. Song, J. Chen, 2017, Oncogene.

Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer.

Justin M Balko, J. Giltnane, J. Balko, 2014, Discovery medicine.

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression

J. Balko, M. Axelrod, D. Franklin, 2020, Cancer drug resistance.

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

E. Winer, K. Polyak, R. Gelman, 2018, npj Breast Cancer.

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

J. Balko, M. Sanders, A. Colaprico, 2021, Nature Communications.

Therapeutics , Targets , and Chemical Biology Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER 2 Homodimers

G. Mills, J. Balko, C. Arteaga, 2011 .

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence

R. Yelensky, H. Gómez, Jenny C. Chang, 2016, Science Translational Medicine.

Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response

J. Balko, Brandie C. Taylor, Brandie C Taylor, 2022, Frontiers in Immunology.

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Yu Shyr, Jonathan M Irish, Anna E Vilgelm, 2016, Nature Communications.

Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

Marieke E. Ijsselsteijn, Pornpimol Charoentong, Z. Trajanoski, 2018, bioRxiv.

Biological Consequences of MHC-II Expression by Tumor Cells in Cancer

Douglas B. Johnson, J. Balko, R. Cook, 2018, Clinical Cancer Research.

If we build it they will come: targeting the immune response to breast cancer

D. Cescon, S. Adams, H. McArthur, 2019, npj Breast Cancer.

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.

J. Balko, M. Sanders, C. Arteaga, 2013, The Journal of clinical investigation.

A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease

H. Gómez, T. Vidaurre, J. Balko, 2016, npj Genomic Medicine.

Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates

Douglas B. Johnson, J. Balko, Yaomin Xu, 2019, Journal of Immunotherapy for Cancer.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

S. Loi, J. Kim, J. Sosman, 2018, JCI insight.

Biomarkers for immune therapy in melanoma

Douglas B. Johnson, J. Balko, Mark R. Johnson, 2018, Seminars in cutaneous medicine and surgery.

Biomarkers for assessing the effectiveness of immunotherapy in breast cancer.

J. Balko, Mellissa J. Nixon, 2018, Biomarkers in medicine.

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

C. Zahnow, J. Balko, M. Sanders, 2018, Nature Communications.

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

A. Mammen, Douglas B. Johnson, J. Balko, 2019, Journal of Immunotherapy for Cancer.

MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC

Joe T. Sharick, S. Cairo, J. Bordeaux, 2020, JCI insight.

Breast Cancer Resistance Mechanisms: Challenges to Immunotherapy

J. Balko, Ann Hanna, 2021, Breast Cancer Research and Treatment.

Pharmacological Activation of cGAS for Cancer Immunotherapy

M. Ascano, J. Balko, John T. Wilson, 2021, Frontiers in Immunology.

Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling*

F. Khuri, T. Owonikoko, Shi-Yong Sun, 2011, The Journal of Biological Chemistry.

If we build it they will come: targeting the immune response to breast cancer

D. Cescon, S. Adams, H. McArthur, 2019, npj Breast Cancer.

PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.

H. Gómez, T. Vidaurre, C. Castañeda, 2014, Hematology/oncology and stem cell therapy.

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT, and MEK/ERK signaling in breast cancer

Wei Yang, W. Hayes McDonald, Carlos L. Arteaga, 2014, Oncogene.

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer

S. Cairo, K. Hutchinson, A. Guerrero-Zotano, 2017, Clinical Cancer Research.

The genomic map of breast cancer: which roads lead to better targeted therapies?

J. Balko, T. Stricker, C. Arteaga, 2013, Breast Cancer Research.

The genomic map of breast cancer: which roads lead to better targeted therapies?

J. Balko, T. Stricker, C. Arteaga, 2013, Breast Cancer Research.

Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with a KRAS Mutation or FGFR1 Gene Amplification

L. Garraway, J. Balko, M. Sanders, 2012, Molecular Cancer Therapeutics.

THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND ENHANCING RESPONSE TO TARGETED EGFR THERAPY

J. Balko, 2009 .

Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors

Anil Potti, Eric B Haura, Justin M Balko, 2006, BMC Genomics.

The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice

A. Gown, T. Nielsen, E. Thompson, 2020, The Journal of pathology.

Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling.

J. Balko, E. Black, J. Britson, 2009, Biochemical and biophysical research communications.

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

G. Mills, M. Dowsett, H. Gómez, 2012, Nature Medicine.

quanTIseq: quantifying immune contexture of human tumors

Gerhard Laschober, Douglas B. Johnson, Dietmar Rieder, 2017 .

Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer

H. Gómez, R. Salgado, J. Balko, 2018, Scientific Reports.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma

J. Witte, T. Ho, J. Kim, 2018, Clinical Cancer Research.

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

William Pao, Vandana G Abramson, Jill Gilbert, 2014, The oncologist.

Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1

J. Balko, Jamaal L. James, 2019, Current Breast Cancer Reports.

A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT

J. Balko, A. Frolov, J. L. Bryant, 2011, British Journal of Cancer.

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.

W. Pao, N. Gray, D. Colvin, 2016, Cancer research.

EPHA2BlockadeOvercomesAcquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

W. Pao, N. Gray, D. Colvin, 2016 .

PD09-06: Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2−Negative Metastatic Breast Cancer (MBC).

J. Balko, Y. Shyr, J. Pietenpol, 2011 .

PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors

L. Cantley, J. Meiler, V. Miller, 2017, Clinical Cancer Research.

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

C. Perou, K. Hutchinson, J. Balko, 2013, The Journal of clinical investigation.

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

E. Winer, M. Berger, L. Cantley, 2019, npj Breast Cancer.

MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC

J. Balko, B. Jones, E. Black, 2009, Cancer biology & therapy.

Combined MEK and EGFR inhibition demonstrates synergistic activity in EGFR-dependent NSCLC

J. Balko, B. Jones, E. Black, 2009 .

A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.

G. Mills, J. Balko, Y. Shyr, 2011, Cancer research.

A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

J. Balko, E. Black, 2009, BMC Cancer.

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Yan Guo, Yu Shyr, Nadia Solovieff, 2019, Nature Communications.

Title: Association of FGFR1 with ER  maintains ligand-independent ER transcription and 1 mediates resistance to estrogen deprivation in ER+ breast cancer 2

S. Cairo, K. Hutchinson, J. Balko, 2017 .

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.

G. Mills, J. Balko, M. V. Estrada, 2014, The Journal of clinical investigation.

Spotlight on Clinical Response Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER þ Breast Cancers with a KRAS Mutation or FGFR 1 Gene Ampli fi cation

L. Garraway, J. Balko, M. Sanders, 2012 .

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

Gordon B Mills, Carlos L Arteaga, Justin M Balko, 2014, Breast Cancer Research.

Molecular Signatures of Lung Cancer

J. Balko, C. Arteaga, 2012, Molecular Diagnosis & Therapy.

Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling

J. Kim, W. Rathmell, J. Bordeaux, 2017, Oncoimmunology.

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

A. Bardia, A. Guerrero-Zotano, J. Balko, 2019, Nature Communications.

Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.

J. Balko, K. Boyd, John T. Wilson, 2020, Journal of controlled release : official journal of the Controlled Release Society.

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

S. Loi, J. Trapani, P. Savas, 2017, Nature Communications.

Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy

Mark Kelley, Dong Soo Yun, Daniel Shae, 2018, Nature Nanotechnology.

G. Boland, Douglas B. Johnson, J. Balko, 2023, Oncoimmunology.

Framework for Implementing and Tracking A Molecular Tumor Board at an NCI-Designated Comprehensive Cancer Center.

Neha M Jain, Douglas B. Johnson, J. Balko, 2021, The oncologist.

Progesterone promotes immunomodulation and tumor development in the murine mammary gland

Howard H. Yang, Ying Hu, K. Hunter, 2021, Journal for ImmunoTherapy of Cancer.

Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms

Zhongming Zhao, Xiangning Chen, Daniel G CHEN, 2021, Breast cancer research : BCR.

TGF-b inhibition enhances chemotherapy action against triple-negative breast cancer

J. Balko, M. Sanders, C. Arteaga, 2018 .

The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium

C. Perou, K. Polyak, K. Hutchinson, 2011, Proceedings of the National Academy of Sciences.

Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade

J. Balko, M. V. Estrada, T. Stricker, 2016, Molecular Cancer Research.

Phase II study of ruxolitinib , a selective JAK 1 / 2 inhibitor , in patients with metastatic triple-negative breast cancer

E. Winer, K. Polyak, R. Gelman, 2018 .

Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.

R. Sullivan, Dennie T. Frederick, J. Sosman, 2016 .

T cell dynamism and immune-related adverse events.

Douglas B. Johnson, J. Balko, 2023, Cancer cell.

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

S. Mallal, J. Sosman, Douglas B. Johnson, 2019, Nature Medicine.

Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Ingrid Meszoely, Sangeeta Bafna, Carlos L Arteaga, 2015, Cancer research.

Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network

Adrian V. Lee, E. Mardis, C. Perou, 2020 .

Actionable Therapeutic Targets Breast Cancers after Neoadjuvant Chemotherapy Identifies Molecular Profiling of the Residual Disease of Triple-Negative

J. Giltnane, J. Balko, Kai Wang, 2014 .

Cancer Positive Breast − in Pretreated Advanced Estrogen Receptor Mutations α Emergence of Constitutively Active Estrogen Receptor-Updated

Funda Meric-Bernstam, Rinath Jeselsohn, Lajos Pusztai, 2014 .

Segal and Dowsett , p . 1724 Emergence of Constitutively Active Estrogen Receptor-a Mutations in Pretreated Advanced Estrogen Receptor – Positive Breast Cancer

James X. Sun, P. Stephens, R. Yelensky, 2014 .

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.

D. Schadendorf, S. Ugurel, R. Sullivan, 2022, European journal of cancer.

A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance

Yu Shyr, Gordon B Mills, Mitch Dowsett, 2011, Clinical Cancer Research.

756 Identifying the role of B7-H4 as a suppressor of tumor infiltrating lymphocytes and a target for immunotherapy in breast cancer

J. Balko, V. Sanchez, M. Sanders, 2021, Journal for ImmunoTherapy of Cancer.

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Clare C. Yu, M. N. Vidya, 2021, npj Breast Cancer.

A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention.

Jing Wang, Y. Li, P. Sharma, 2020, Cancer discovery.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

S. Mallal, R. Yelensky, S. Loi, 2019, Clinical Cancer Research.

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

S. Mallal, S. Loi, R. Salgado, 2020, Clinical Cancer Research.

Abstract LB-056: Quantitative mass spectrometry analysis of immune checkpoint protein expression and N-glycosylation in human melanoma

Douglas B. Johnson, J. Balko, D. Liebler, 2017 .

Triple-Negative Breast Cancer

J. Balko, I. Mayer, S. Nunnery, 2021, Cancer journal.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

Molecular characterization of immune-related severe adverse events (irSAE).

J. Sosman, Douglas B. Johnson, J. Balko, 2017 .

Role of JAK-STAT Pathway in Cancer Signaling

J. Balko, N. Luo, 2018, Predictive Biomarkers in Oncology.

Abstract P1-13-08: Extended adjuvant neratinib/fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ tumors following treatment with chemotherapy and anti-HER2 therapy

Sudhan, A. Guerrero-Zotano, J. Balko, 2018 .

Assembly and Function of the Regulator of G protein Signaling 14 ( RGS 14 ) · HRas Signaling Complex in Live Cells Are Regulated by G α i 1 and G α i-linked G Protein-coupled Receptors

F. Khuri, T. Owonikoko, Shi-Yong Sun, 2022 .

In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies

H. Gómez, J. Balko, C. Rolfo, 2017, Scientific Reports.

Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple negative breast cancer.

Carlos L. Arteaga, K. Hutchinson, V. Malladi, 2022, Cancer immunology research.

ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation

J. Balko, M. M. Joly, R. Cook, 2017, Breast Cancer Research.

Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer

J. Balko, C. Hagan, Katherine R. Walter, 2020, Oncoimmunology.

STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy

J. Balko, J. Rathmell, John T. Wilson, 2023, Science Immunology.

Abstract 4875: Human HER2 and PI3K H1047R cooperate to promote mammary tumorigenesis in vivo

Charles M. Perou, Rebecca S. Cook, Carlos L. Arteaga, 2012 .

PD09-05: SU2C Phase Ib Study of pan-PI3K Inhibitor BKM120 Plus Aromatase Inhibitor Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC).

E. Winer, J. Yap, J. Balko, 2011 .

Demographic Factors Associated with Toxicity in Patients Treated with Anti–Programmed Cell Death-1 Therapy

Douglas B. Johnson, J. Balko, J. Moslehi, 2020, Cancer Immunology Research.

Interactive network-based clustering and investigation of multimorbidity association matrices with associationSubgraphs

Jana K. Shirey-Rice, D. Roden, D. Ruderfer, 2022, medRxiv.

Abstract P6-10-05: SU2C Phase 1b Trial of Dual PI3K/ mTOR Inhibitor BEZ235 with Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC)

E. Winer, J. Balko, M. Sanders, 2012 .

Do the genes tell us the path of most resistance?

J. Balko, E. P. Black, 2011, Cancer biology & therapy.

Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer

B. Seliger, A. Guerrero-Zotano, J. Balko, 2022, Cancer research communications.

Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome

X. Shu, W. Zheng, W. Lu, 2014, Breast Cancer Research and Treatment.

Dead-box or black-box: is DDX1 a potential biomarker in breast cancer?

J. Balko, C. Arteaga, 2011, Breast Cancer Research and Treatment.

Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities

Douglas B. Johnson, J. Balko, Seungyeon Jung, 2023, Immunological reviews.

A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer.

H. Gómez, J. Balko, M. Sanders, 2012 .

Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.

J. Balko, S. Swain, A. Tan, 2021 .

Correction to: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

Marieke E. Ijsselsteijn, Pornpimol Charoentong, Z. Trajanoski, 2019, Genome Medicine.

Correction to: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

Z. Trajanoski, Douglas B. Johnson, J. Balko, 2019, Genome Medicine.

Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms.

J. Balko, C. Arteaga, 2012, Molecular diagnosis & therapy.

Convolutional neural network for biomarker discovery for triple negative breast cancer with RNA sequencing data.

J. Balko, Xiangning Chen, Jingchun Chen, 2023, Heliyon.

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

E. Winer, M. Berger, L. Cantley, 2019, npj Breast Cancer.

Abstract S3-6: Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease

R. Yelensky, M. Cronin, H. Gómez, 2012 .

Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.

J. Balko, H. Koblish, P. Scherle, 2018, Cancer research.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

L. Garraway, X. Mu, R. Yelensky, 2017, Science Translational Medicine.

Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling.

J. Balko, E. Black, F. Barton, 2009, Biochemical and biophysical research communications.

Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.

C. Perou, J. Balko, Hailing Cheng, 2013, Cancer research.

Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

K. Gelmon, M. Gnant, C. Isaacs, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer

Robert E. Brown, G. Mills, H. Gómez, 2013, Clinical Cancer Research.

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis

E. Ziv, J. Balko, M. Aldrich, 2024, Nature communications.

Automated Dissection Protocol for Tumor Enrichment in Low Tumor Content Tissues.

Amy A. Lo, J. Giltnane, J. Balko, 2021, Journal of visualized experiments : JoVE.

A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.

G. Mills, J. Balko, Y. Shyr, 2011, Cancer research.

Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer

L. Esserman, J. Balko, J. Pietenpol, 2024, Cancer research communications.